BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 31644323)

  • 1.
    Jain S; Abraham A
    Arch Pathol Lab Med; 2020 Feb; 144(2):150-155. PubMed ID: 31644323
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tyrosine kinase fusion genes in pediatric BCR-ABL1-like acute lymphoblastic leukemia.
    Boer JM; Steeghs EM; Marchante JR; Boeree A; Beaudoin JJ; Beverloo HB; Kuiper RP; Escherich G; van der Velden VH; van der Schoot CE; de Groot-Kruseman HA; Pieters R; den Boer ML
    Oncotarget; 2017 Jan; 8(3):4618-4628. PubMed ID: 27894077
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BCR/ABL1-Like Acute Lymphoblastic Leukemia: From Diagnostic Approaches to Molecularly Targeted Therapy.
    Płotka A; Lewandowski K
    Acta Haematol; 2022; 145(2):122-131. PubMed ID: 34818644
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BCR-ABL1-like acute lymphoblastic leukaemia: From bench to bedside.
    Boer JM; den Boer ML
    Eur J Cancer; 2017 Sep; 82():203-218. PubMed ID: 28709134
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Philadelphia chromosome-like acute lymphoblastic leukemia.
    Tasian SK; Loh ML; Hunger SP
    Blood; 2017 Nov; 130(19):2064-2072. PubMed ID: 28972016
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High incidence of RAS pathway mutations among sentinel genetic lesions of Korean pediatric BCR-ABL1-like acute lymphoblastic leukemia.
    Lee JW; Kim Y; Cho B; Kim S; Jang PS; Lee J; Cho H; Lee GD; Chung NG; Kim M
    Cancer Med; 2020 Jul; 9(13):4632-4639. PubMed ID: 32378810
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BCR-ABL1-like B-lymphoblastic leukemia/lymphoma: Review of the entity and detection methodologies.
    Conant JL; Czuchlewski DR
    Int J Lab Hematol; 2019 May; 41 Suppl 1():126-130. PubMed ID: 31069976
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Beneficial tyrosine kinase inhibitor therapy in a patient with relapsed BCR-ABL1-like acute lymphoblastic leukemia with CCDC88C-PDGFRB fusion.
    Oya S; Morishige S; Ozawa H; Sasaki K; Semba Y; Yamasaki Y; Nakamura T; Aoyama K; Seki R; Mouri F; Osaki K; Miyamoto T; Maeda T; Nagafuji K
    Int J Hematol; 2021 Feb; 113(2):285-289. PubMed ID: 32951102
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 'Evaluation of adverse prognostic gene alterations & MRD positivity in BCR::ABL1-like B-lineage acute lymphoblastic leukaemia patients, in a resource-constrained setting.
    Gupta DG; Varma N; Sreedharanunni S; Abdulkadir SA; Naseem S; Sachdeva MUS; Binota J; Bose P; Malhotra P; Khadwal A; Varma S
    Br J Cancer; 2023 Jul; 129(1):143-152. PubMed ID: 37156894
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Outcomes of children with BCR-ABL1–like acute lymphoblastic leukemia treated with risk-directed therapy based on the levels of minimal residual disease.
    Roberts KG; Pei D; Campana D; Payne-Turner D; Li Y; Cheng C; Sandlund JT; Jeha S; Easton J; Becksfort J; Zhang J; Coustan-Smith E; Raimondi SC; Leung WH; Relling MV; Evans WE; Downing JR; Mullighan CG; Pui CH
    J Clin Oncol; 2014 Sep; 32(27):3012-20. PubMed ID: 25049327
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Laboratory testing in BCR-ABL1-like (Philadelphia-like) B-lymphoblastic leukemia/lymphoma.
    Siegele BJ; Nardi V
    Am J Hematol; 2018 Jul; 93(7):971-977. PubMed ID: 29696694
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MUC4 expression by immunohistochemistry is a specific marker for
    Kaumeyer B; Fidai S; Sukhanova M; Yap KL; Segal J; Raca G; Stock W; McNeer J; Lager AM; Gurbuxani S
    Leuk Lymphoma; 2022 Jun; 63(6):1436-1444. PubMed ID: 35171727
    [No Abstract]   [Full Text] [Related]  

  • 13. A novel targeted RNA-Seq panel identifies a subset of adult patients with acute lymphoblastic leukemia with BCR-ABL1-like characteristics.
    Sánchez R; Ribera J; Morgades M; Ayala R; Onecha E; Ruiz-Heredia Y; Juárez-Rufián A; de Nicolás R; Sánchez-Pina J; Vives S; Zamora L; Mercadal S; Coll R; Cervera M; García O; Ribera JM; Martínez-López J
    Blood Cancer J; 2020 Apr; 10(4):43. PubMed ID: 32332702
    [TBL] [Abstract][Full Text] [Related]  

  • 14. From the archives of MD Anderson Cancer Center: Concurrent BCR-ABL1 and CRLF2 rearrangements in B-lymphoblast phase of chronic myeloid leukemia.
    Thakral B; Jain N; Tang G; Konoplev S; Vega F; Medeiros LJ; Wang SA
    Ann Diagn Pathol; 2021 Aug; 53():151767. PubMed ID: 34118580
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BCR/ABL1-like acute lymphoblastic leukemia: How to diagnose and treat?
    Chiaretti S; Messina M; Foà R
    Cancer; 2019 Jan; 125(2):194-204. PubMed ID: 30561755
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targetable kinase gene fusions in high-risk B-ALL: a study from the Children's Oncology Group.
    Reshmi SC; Harvey RC; Roberts KG; Stonerock E; Smith A; Jenkins H; Chen IM; Valentine M; Liu Y; Li Y; Shao Y; Easton J; Payne-Turner D; Gu Z; Tran TH; Nguyen JV; Devidas M; Dai Y; Heerema NA; Carroll AJ; Raetz EA; Borowitz MJ; Wood BL; Angiolillo AL; Burke MJ; Salzer WL; Zweidler-McKay PA; Rabin KR; Carroll WL; Zhang J; Loh ML; Mullighan CG; Willman CL; Gastier-Foster JM; Hunger SP
    Blood; 2017 Jun; 129(25):3352-3361. PubMed ID: 28408464
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BCR-ABL1-like B-Lymphoblastic Leukemia/Lymphoma with FOXP1-ABL1 Rearrangement: Comprehensive Laboratory Identification Allowing Tyrosine Kinase Inhibitor Use.
    Yenamandra AK; Kaviany S; Borinstein SC; Friedman DL; Kovach AE
    Lab Med; 2019 Oct; 50(4):401-405. PubMed ID: 30938769
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia.
    Roberts KG; Li Y; Payne-Turner D; Harvey RC; Yang YL; Pei D; McCastlain K; Ding L; Lu C; Song G; Ma J; Becksfort J; Rusch M; Chen SC; Easton J; Cheng J; Boggs K; Santiago-Morales N; Iacobucci I; Fulton RS; Wen J; Valentine M; Cheng C; Paugh SW; Devidas M; Chen IM; Reshmi S; Smith A; Hedlund E; Gupta P; Nagahawatte P; Wu G; Chen X; Yergeau D; Vadodaria B; Mulder H; Winick NJ; Larsen EC; Carroll WL; Heerema NA; Carroll AJ; Grayson G; Tasian SK; Moore AS; Keller F; Frei-Jones M; Whitlock JA; Raetz EA; White DL; Hughes TP; Guidry Auvil JM; Smith MA; Marcucci G; Bloomfield CD; Mrózek K; Kohlschmidt J; Stock W; Kornblau SM; Konopleva M; Paietta E; Pui CH; Jeha S; Relling MV; Evans WE; Gerhard DS; Gastier-Foster JM; Mardis E; Wilson RK; Loh ML; Downing JR; Hunger SP; Willman CL; Zhang J; Mullighan CG
    N Engl J Med; 2014 Sep; 371(11):1005-15. PubMed ID: 25207766
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Mutations in the BCR-ABL1 gene in a peruvian patient with acute lymphoblastic leukemia resistant to therapy].
    Ortiz CA; Alvarez YP; Dongo-Pflucker KL; Valdivia E; Mendoza Fernández J; Dávila S; Mora-Alférez P
    Rev Fac Cien Med Univ Nac Cordoba; 2017; 74(2):162-166. PubMed ID: 28657534
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rapid molecular response to dasatinib in Ph-like acute lymphoblastic leukemia patients with ABL1 rearrangements: case series and literature review.
    Tan KW; Zhu YY; Qiu QC; Wang M; Shen HJ; Huang SM; Cao HY; Wan CL; Li YY; Dai HP; Xue SL
    Ann Hematol; 2023 Sep; 102(9):2397-2402. PubMed ID: 37103615
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.